Voyager Therapeutics (NASDAQ:VYGR) Shares Gap Up to $9.26

Voyager Therapeutics, Inc. (NASDAQ:VYGR)’s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $9.26, but opened at $9.89. Voyager Therapeutics shares last traded at $9.99, with a volume of 221,271 shares changing hands.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the stock. StockNews.com upgraded shares of Voyager Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, March 9th. Guggenheim assumed coverage on shares of Voyager Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $22.00 price objective for the company. Wells Fargo & Company upgraded shares of Voyager Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $9.00 to $14.00 in a research report on Tuesday, January 2nd. Citigroup began coverage on shares of Voyager Therapeutics in a research report on Thursday, March 7th. They issued a “buy” rating and a $16.00 price objective for the company. Finally, HC Wainwright began coverage on shares of Voyager Therapeutics in a research report on Tuesday, March 19th. They set a “buy” rating and a $30.00 price target for the company. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, Voyager Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $19.33.

Voyager Therapeutics Trading Down 4.6 %

The company’s 50 day moving average price is $8.33 and its 200-day moving average price is $7.84. The company has a market capitalization of $519.11 million, a PE ratio of 3.09 and a beta of 0.96.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings data on Wednesday, February 28th. The company reported $1.25 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $1.84. The company had revenue of $90.06 million during the quarter, compared to analysts’ expectations of $4.95 million. Voyager Therapeutics had a net margin of 52.93% and a return on equity of 63.89%. As a group, analysts predict that Voyager Therapeutics, Inc. will post -1.64 earnings per share for the current year.

Hedge Funds Weigh In On Voyager Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Armistice Capital LLC lifted its holdings in shares of Voyager Therapeutics by 1.4% during the 4th quarter. Armistice Capital LLC now owns 4,236,000 shares of the company’s stock valued at $35,752,000 after acquiring an additional 58,000 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Voyager Therapeutics by 1.9% in the 4th quarter. Vanguard Group Inc. now owns 2,529,668 shares of the company’s stock worth $21,350,000 after buying an additional 47,711 shares in the last quarter. BlackRock Inc. lifted its holdings in Voyager Therapeutics by 200.7% in the 2nd quarter. BlackRock Inc. now owns 2,477,400 shares of the company’s stock worth $28,366,000 after buying an additional 1,653,613 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in Voyager Therapeutics by 19.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 932,231 shares of the company’s stock worth $7,869,000 after buying an additional 153,291 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its holdings in Voyager Therapeutics by 13.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 901,465 shares of the company’s stock worth $6,951,000 after buying an additional 104,144 shares in the last quarter. Institutional investors and hedge funds own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.